

Scan the QR code  
The QR code is intended  
to provide scientific  
information for individual  
reference and the  
information should not  
be altered or reproduced  
in any way.

Northwestern Medicine Digestive Health Institute, Chicago, IL, USA; <sup>2</sup>Johnson & Johnson, Spring House, PA, USA; <sup>3</sup>Department of Gastroenterology and Hepatology, Kyorin University, Tokyo, Japan; <sup>4</sup>Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; <sup>5</sup>Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy; <sup>6</sup>Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; <sup>7</sup>University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA

---

To evaluate the pharmacokinetics (PK) and exposure-response of IV and SC guselkumab induction in participants with moderately to severely active UC

**AUC**<sub>week 0-12</sub>=area under the concentration-time curve from week 0 to week 12 (induction), **C**<sub>max, week 0-12</sub>=average concentration from week 0 to week 12 (induction), **C**<sub>max, week 8</sub>=maximum concentration at week 8, **C**<sub>trough, week 12</sub>=trough concentration at week 12, **IV**=intravenous, **PK**=pharmacokinetics, **SC**=subcutaneous.

Clinical remission, clinical response, and endoscopic improvement are based on the modified Mayo score, which consists of three components—the stool frequency, rectal bleeding, and endoscopic subscores.